

**DUR Committee Agenda  
April 14<sup>th</sup>, 2015**

**Office of MaineCare Services, Department of Health and Human Services  
Augusta Armory  
Augusta, Maine  
6:00 to 8:00 pm**

**Call to Order: 6:00 pm**

**Public Comments - Open Session**

**Old Business:**

**Approval of March Minutes (5 mins)**

**MaineCare Update**

**Closed Session:**

**Financial Discussion (10 mins)**

**Contracts (10 mins)**

**New Business:**

**A) Amiodarone DDI**

**B) Gardasil- 9**

**C) New Drug Review**

**Duavee            Prezcobix**

**Ibrance            Pazeo drops**

**Glyxambi        Lenvima**

**Movantik        Vitakta**

**Rasuvo           Rytary**

**Evotaz**

**FDA Safety Alerts (10 mins)**

Chantix (varenicline): Drug Safety Communication - FDA Updates Label to Include Potential Alcohol Interaction

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm437415.htm>

FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni or Sovaldi) in combination with another Direct Acting Antiviral drug

[http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)

Zyprexa Relprevv (olanzapine pamoate): Drug Safety Communication- FDA Review of Study Sheds Light on Two Deaths Associated with the Injectable Schizophrenia Drug

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm439472.htm>

**Nationwide Alert: DEA Calls Opioid a Serious Public Health Threat**

**Next meeting: May 12<sup>th</sup> 2015 6-8pm**

**Adjournment: 8:00 pm**